|
Sunday, 08/03/2014
|
Regression for Skewed Biomarker Outcomes Subject to Pooling
Emily Mitchell, NICHD; Robert Lyles, Emory University; Amita K. Manatunga, Emory University; Michelle Danaher, University of Maryland Baltimore County; Neil Perkins, NICHD; Enrique Schisterman, NICHD
2:05 PM
|
Characterizing Expected Benefits of Biomarkers in Treatment Selection
Ying Huang, Fred Hutchinson Cancer Research Center; Eric B. Laber, North Carolina State University; Holly Janes, Fred Hutchinson Cancer Research Center
2:45 PM
|
Classification Trees and Covariates: Applications in Neuroscience
Josephine Asafu-Adjei, Harvard School of Public Health; Allan Sampson, University of Pittsburgh
2:55 PM
|
Filtering, Bias, and Biomarker Identification
Gregory Hather, Takeda; Ray Liu, Takeda
4:05 PM
|
A Nonparametric Visualization Method to Measuring the Potential of Biomarkers for Guiding Treatment Decisions
Hui Yang, Amgen; Rui (Sammi) Tang, Amgen; Michael Hale, Amgen; Jing Huang, Amgen
4:20 PM
|
Multi-Layered Data Classification for Biomarker Discovery
Samuel Mueller, University of Sydney; Ellis Patrick, University of Sydney; Jean Yee Hwa Yang, University of Sydney
4:25 PM
|
Biomarker Signatures for Patient Subgroup Selection in Clinical Drug Development
Xin Huang, AbbVie; Paul Trow, AbbVie; Yan Sun, AbbVie; Viswanath Devanarayan, AbbVie
4:35 PM
|
Improved Understanding of Huntington's Disease Onset Through a Genetic Mixture Model with Genetic Biomarkers and Distribution-Free Random Effects
Tanya Garcia, Texas A&M; Yuanjia Wang, Columbia University; Yanyuan Ma, Texas A&M; Karen Marder, Columbia University
4:45 PM
|
Big Data for Medical Research: A Unified Approach for Individualized Treatment Recommendation and Subgroup Identification Based on Electronic Medical Record Data
Haoda Fu, Eli Lilly and Company; Jin Zhou, University of Arizona
4:50 PM
|
Development of Genetic Biomarkers in Drug Discovery and Early Drug Development Experiments
Nolen Joy Perualila, Hasselt University; Ziv Shkedy, Hasselt University; Adetayo Kasim, Durham University
5:05 PM
|
Transform-Both-Sides Nonlinear Mixed Effects Models for Multiple Flow Exhaled Nitric Oxide Data
Sandrah P. Eckel, University of Southern California; Noa Molshatzki, University of Southern California
5:05 PM
|
Regularized Longitudinal Regression to Detect Biomarkers for Nephrotic Syndromes
Peter Song, University of Michigan
5:20 PM
|
Biomarker-Based Dose-Finding Designs for Single- or Multiple-Agent Phase I Trials
Yuan Xue, University of Virginia; Mark Conaway, University of Virginia; Feifang Hu, George Washington University
5:20 PM
|
|
Monday, 08/04/2014
|
Identifying Patient-Specific Biomarker and Predicting Anti-Cancer Drug Sensitivity via Robust Statistical Methodology
Heewon Park, University of Tokyo; Teppei Shimamura, University of Tokyo; Seiya Imoto, University of Tokyo; Satoru Miyano, University of Tokyo
|
Predicting Patients' Responses to Treatment for Personalized Medicine
Wei-Jiun Lin, Feng Chia University; James J. Chen, NCTR/FDA
|
An Investigation into the Effect of Selection Bias on Multiple Biomarker Models: A Simulation Study
Tristan Grogan, University of California, Los Angeles; David Elashoff, University of California, Los Angeles
|
Novel Statistical Network Methodology to Identify and Analyze Cancer Biomarkers
Thomas Bartlett; Sofia Olhede, University College London; Alexey Zaikin, University College London
|
Novel Statistical Network Methodology to Identify and Analyze Cancer Biomarkers
Thomas Bartlett; Sofia Olhede, University College London; Alexey Zaikin, University College London
9:15 AM
|
Selection of Development Pathways with Established or Exploratory Biomarkers
Ming-Xiu Hu, Takeda; Yi Liu, Takeda; Feng Gao, Takeda
9:15 AM
|
A Phase II--III Design with Biomarker-Guided Subpopulation Selection and Its Application to a Case Study of NCIC CTG Trial
Keyue Ding, Queen's University
9:50 AM
|
Clinical Utility Estimation for Assay Cut-Offs in Early-Phase Oncology Enrichment Trials
Jared Lunceford, Merck
10:35 AM
|
Exploring Network Analysis for a Resting-State fMRI Study for Alzheimer Imaging Biomarker Research
Yuefeng Lu
10:55 AM
|
On Efficient Use of Logistic Regression When a Continuous Biomarker Is Assayed on Pooled Biospecimens
Robert Lyles, Emory University; Emily Mitchell, NICHD; Clarice Weinberg, NIEHS; David M. Umbach, NIEHS; Enrique Schisterman, NICHD
11:20 AM
|
Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials
Yanxun Xu; Lorenzo Trippa, Harvard School of Public Health; Peter Mueller, University of Texas at Austin; Yuan Ji, NorthShore University HealthSystem
11:35 AM
|
Using Ordered Values of Longitudinal Changes in Regional Knee Cartilage Thickness as an Efficacy Biomarker in Osteoarthritis
Robert Buck, StatAnswers Consulting LLC
11:35 AM
|
Adjusting for Misclassification in the Design and Analysis of Stratified Biomarker Clinical Trials
Susan Halabi, Duke University; Chen-Yen Lin, Eli Lilly and Company; Aiyi Liu, NICHD
2:35 PM
|
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: a Study of Pca3 and Prostate Cancer
Jeanette Birnbaum, University of Washington; Ziding Feng, MD Anderson Cancer Center; Jing Fan, University of Washington; Roman Gulati, Fred Hutchinson Cancer Research Center; Ruth Etzioni, Fred Hutchinson Cancer Research Center
3:05 PM
|
Coupling Model Selection with Evaluation in Prognostic Model Development
Aasthaa Bansal, University of Washington; Patrick Heagerty, University of Washington
3:20 PM
|
Imputing Biomarker Outcome Refusals and Unasked Questions in a Nonresponse Follow-Up for Environmental Exposure Models
Brian M. Wells, University of Michigan; James Lepkowski, University of Michigan
3:20 PM
|
|
Tuesday, 08/05/2014
|
Optimal Normality Transformation Methods for the Analysis of Biomarkers
Kelly Zou, Pfizer; Ching-Ray Yu, Pfizer; Martin O. Carlsson, Pfizer; Ye Tan, Pfizer
|
Metabolomics-Based Discovery of Diagnostic Biomarkers for Dengue
Carolyn Cotterman; Natalia Voge, Colorado State University; Rushika Perera, Colorado State University ; Lionel Gresh, Sustainable Sciences Institute; Carol Blair, Colorado State University; Hope Biswas, University of California, Berkeley; Angel Balmaseda, Ministry of Health, Nicaragua; Eva Harris, University of California, Berkeley; Barry Beaty, Colorado State University
|
Statistical Analysis of Neuroimaging Data: Past Methods, Current Challenges, and Opportunities
DuBois Bowman, Columbia University
|
Statistical Interaction Term to Assess Treatment Effect in Biomarker Analysis
Dung-Tsa Chen, Moffitt Cancer Center & Research Institute; James J. Chen, NCTR/FDA; Ying-Lin Hsu, National Chung Hsing University, Taiwan; Po-Yu Huang, National Chung Hsing University, Taiwan
|
Ensemble-Based Feature Selection for Bayesian Integration Models to Improve Biomarker Panel Identification
Bobbie-Jo Webb-Robertson, Pacific Northwest National Laboratory; Marian Rewers, University of Colorado; Qibin Zhang, Pacific Northwest National Laboratory; Katrina Waters, Pacific Northwest National Laboratory; Thomas Metz, Pacific Northwest National Laboratory
|
Dose-Finding Designs for Phase I Clinical Trials in Oncology and Use of Selective Phenotypying to Increase Power of Genetic Association Studies
Yunfei Wang, Children's National Medical Center; Ethan M. Lange, University of North Carolina
10:05 AM
|
Practical Enhancements to the Adaptive Signature Type of Design
Jonathan Denne, Eli Lilly and Company; Adarsh Joshi, Gilead; Lei Shen, Eli Lilly and Company; Peigang Li, Eli Lilly and Company; Hollins Showalter, Eli Lilly and Company; Eric Nantz, Eli Lilly and Company
10:55 AM
|
Censored Functional Data with Application to a Mortality Study in the ICU
Jonathan Gellar, Johns Hopkins Bloomberg School of Public Health; Elizabeth Colantuoni, Johns Hopkins Bloomberg School of Public Health; Dale M. Needham, Johns Hopkins University; Ciprian Crainiceanu, Johns Hopkins University
10:55 AM
|
Statistical Interaction Term to Assess Treatment Effect in Biomarker Analysis
Dung-Tsa Chen, Moffitt Cancer Center & Research Institute; James J. Chen, NCTR/FDA; Ying-Lin Hsu, National Chung Hsing University, Taiwan; Po-Yu Huang, National Chung Hsing University, Taiwan
10:55 AM
|
Ensemble-Based Feature Selection for Bayesian Integration Models to Improve Biomarker Panel Identification
Bobbie-Jo Webb-Robertson, Pacific Northwest National Laboratory; Marian Rewers, University of Colorado; Qibin Zhang, Pacific Northwest National Laboratory; Katrina Waters, Pacific Northwest National Laboratory; Thomas Metz, Pacific Northwest National Laboratory
11:00 AM
|
The Application of Group Sequential Stopping Boundaries to Evaluate the Treatment Effect of an Experimental Agent Across a Range of Marker Expression
Eric Holmgren, Oncomed
11:15 AM
|
The STEPP Approach to Assessing Treatment-Effect Heterogeneity for Relative and Absolute Endpoints
Ann Lazar, University of California, San Francisco; Marco Bonetti, Bocconi University; Bernard F. Cole, University of Vermont; Wai-ki Yip, Harvard School of Public Health; Richard D. Gelber, Harvard School of Public Health/Dana-Farber Cancer Institute
11:20 AM
|
Dynamic Prediction of Time-to-Disease Progression Using Longitudinal Biomarker Data
Xuelin Huang, MD Anderson Cancer Center; Sangbum Choi, University of Texas at Houston; Jing Ning, MD Anderson Cancer Center
11:55 AM
|
Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase III Dose Selection
Bret Musser, Merck; Ghassan Fayad, Merck; Yue Shentu, Bausch and Lomb; James A. Bolognese, Cytel; Nitin Patel, Cytel; Jaydeep Bhattacharyya, Cytel
2:05 PM
|
Estimating Biological Age Using Ensemble-Based Prediction Models in Genomic Data
Wendy Shih, University of California, Los Angeles; Steve Horvath, University of California, Los Angeles; Roel Ophoff, University of California, Los Angeles
2:20 PM
|
|
Wednesday, 08/06/2014
|
Identifying Subgroups of Enhanced Predictive Accuracy from Longitudinal Biomarker Data with Applications to Monitoring Fetal Growth
Jared Foster, NICHD; Danping Liu, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Aiyi Liu, NICHD; Paul Albert, Eunice Kennedy Shriver National Institute of Child Health and Human Development
9:35 AM
|
Toward a Multimodal Characterization of Chronic Traumatic Encephalopathy
Laura Mariano, Charles Stark Draper Laboratory; John Irvine, Charles Stark Draper Laboratory; Alexander Lin, Brigham & Women's Hospital; Yorghos Tripodis, Boston University School of Public Health; Robert Stern, Boston University School of Medicine
9:50 AM
|
New Developments in Machine Learning for Personalized Medicine
Michael Kosorok, University of North Carolina at Chapel Hill
10:35 AM
|
Discovery Among Binary Biomarkers
Elizabeth H. Slate, Florida State University; Junxian Geng, Florida State University; Bethany A. Wolf, Medical University of South Carolina; Elizabeth G. Hill, Medical University of South Carolina
10:35 AM
|
A Bayesian Approach to Biomarker Selection Through MiRNA Regulatory Network with Application to Kidney Cancer
Thierry Chekouo, MD Anderson Cancer Center; Francesco Stingo, MD Anderson Cancer Center; James Doecke, CSIRO Computational Informatics; Kim-Ahn Do, MD Anderson Cancer Center
10:50 AM
|
Using Repeated Measures to Aid Cut Point Selection
Zhezhen Jin, Columbia University; Xinhua Liu, Columbia University
10:55 AM
|
Model Selection Based on Quadratic Distances Between Distributions with Application to an HCV Biomarker
Rositsa Dimova, University at Buffalo; Marianthi Markatou, University at Buffalo
11:05 AM
|
Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs
Dandan Liu, Vanderbilt University; Tianxi Cai, Harvard; Lok Anna, University of Michigan; Yingye Zheng, Fred Hutchinson Cancer Research Center
2:05 PM
|
New Graphical Approach for Visualization of EMR Data with Application to Biomarker Studies
Christine Duarte, Maine Medical Center; Ivette Emery, MMCRI; Andrew Prueser, MMCRI; Volkhard Lindner, MMCRI
2:35 PM
|
Methods for Covariate Adjustment in Combing Multiple Markers
Soyoung Kim, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center
3:35 PM
|
|
Thursday, 08/07/2014
|
Testing Strategies for Trial Designs with Prognostic Biomarkers
Chris Holland, Amgen; Catherine Jia, Amgen; Alicia Zhang, Amgen
8:35 AM
|
Empirical Likelihood Ratio Confidence Interval Estimation of Best Linear Combination of Biomarkers
Xiwei Chen; Albert Vexler, University at Buffalo; Marianthi Markatou, University at Buffalo
8:35 AM
|
Blocking and Randomization to Improve Molecular Biomarker Discovery
Li-Xuan Qin, Memorial Sloan Kettering Cancer Center; Qin Zhou, Memorial Sloan Kettering Cancer Center; Jaya Satagopan, Memorial Sloan Kettering Cancer Center; Colin Begg, Memorial Sloan Kettering Cancer Center; Douglas Levine, Memorial Sloan Kettering Cancer Center
8:50 AM
|
Accounting for Biomarker-Based Subpopulation Selection in Phase II Trials in POS Computations
Guochen Song, Quintiles; Ilya Lipkovich, Quintiles; Alex Dmitrienko, Quintiles
8:50 AM
|
Statistical Methodology for Multiclass Classifications Applications to Dementia
Hong Li, Rush UMC; Sue Leurgans, Rush UMC
9:20 AM
|
Inter-Lab Calibration of Biomarker Data with Censoring
Shizhe Chen, University of Washington; Yunda Huang, Fred Hutchinson Cancer Research Center; Xiao-Hua Andrew Zhou, University of Washington
9:35 AM
|
Detecting Treatment Pathway Interaction in Small Clinical Studies
Jia Kang, Merck
9:35 AM
|
Weighted Analyses of Randomized Clinical Trials with Treatment Noncompliance and Biomarker Information Collected from a Cohort Subsample
Shuli Li; Robert J. Gray, Dana-Farber Cancer Institute
9:50 AM
|
On Regression Models When the Predictor Is Subject to Censoring
David Oakes, University of Rochester
10:35 AM
|
Biomarker-Based Clinical Trials: an Overview
Daniel Sargent, Mayo Clinic; William Barry, Dana-Farber Cancer Institute
10:35 AM
|
Statistical Issues in Developing Predictive Biomarkers in Drug Clinical Trials
Nusrat Rabbee
10:35 AM
|
An Application of the Best Linear Unbiased Estimators (BLUE) for Missing Biomarkers Values in the Analysis of Repeated Measurements in Oncology Clinical Trials
Santosh Sutradhar, Novartis; D. Das Purkayastha, Novartis
10:50 AM
|
Biomarker Driven Population Enrichment for Adaptive Oncology Trials
Cyrus Mehta, Cytel
10:55 AM
|
Immunobridging Formula for Predicting Vaccine Efficacy, Accounting for Baseline Covariates, Post-Baseline Biomarker Surrogate Endpoints, and Geno/Serotypes of Circulating Pathogens
Peter Gilbert, Fred Hutchinson Cancer Research Center
11:15 AM
|
Implementation of NGS Genomics Data in Oncology Clinical Trials: Analytical Issues and Lessons Learned
Ray Liu, Takeda; Feng Gao, Takeda; Jacob Zhang, Takeda
11:35 AM
|
Biomarker-Based N-of-1 Trials for Addressing Patient Heterogeneity in Personalized Medicine
Yining Du, MD Anderson Cancer Center; Jack Lee, MD Anderson Cancer Center
11:50 AM
|
|
Copyright © American Statistical Association.